201 related articles for article (PubMed ID: 18227226)
1. Development of a fission yeast-based high-throughput screen to identify chemical regulators of cAMP phosphodiesterases.
Ivey FD; Wang L; Demirbas D; Allain C; Hoffman CS
J Biomol Screen; 2008 Jan; 13(1):62-71. PubMed ID: 18227226
[TBL] [Abstract][Full Text] [Related]
2. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Biochem Pharmacol; 2005 Jan; 69(2):267-75. PubMed ID: 15627479
[TBL] [Abstract][Full Text] [Related]
4. A fission yeast-based platform for phosphodiesterase inhibitor HTSs and analyses of phosphodiesterase activity.
Demirbas D; Ceyhan O; Wyman AR; Hoffman CS
Handb Exp Pharmacol; 2011; (204):135-49. PubMed ID: 21695638
[TBL] [Abstract][Full Text] [Related]
5. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
[TBL] [Abstract][Full Text] [Related]
6. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
[TBL] [Abstract][Full Text] [Related]
7. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse.
Cherry JA; Thompson BE; Pho V
Biochim Biophys Acta; 2001 Mar; 1518(1-2):27-35. PubMed ID: 11267656
[TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase.
Fisher DA; Smith JF; Pillar JS; St Denis SH; Cheng JB
Biochem Biophys Res Commun; 1998 May; 246(3):570-7. PubMed ID: 9618252
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain.
Iona S; Cuomo M; Bushnik T; Naro F; Sette C; Hess M; Shelton ER; Conti M
Mol Pharmacol; 1998 Jan; 53(1):23-32. PubMed ID: 9443929
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
11. Studying mechanisms of cAMP and cyclic nucleotide phosphodiesterase signaling in Leydig cell function with phosphoproteomics.
Golkowski M; Shimizu-Albergine M; Suh HW; Beavo JA; Ong SE
Cell Signal; 2016 Jul; 28(7):764-78. PubMed ID: 26643407
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of a phosphodiesterase III in the lysis-sensitive target-induced elevation of cyclic AMP (cAMP) in human natural killer cells.
Whalen MM; Crews JD
Biochem Pharmacol; 2000 Aug; 60(4):499-506. PubMed ID: 10874124
[TBL] [Abstract][Full Text] [Related]
13. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
[TBL] [Abstract][Full Text] [Related]
14. The Schizosaccharomyces pombe pde1/cgs2 gene encodes a cyclic AMP phosphodiesterase.
Matviw H; Li J; Young D
Biochem Biophys Res Commun; 1993 Jul; 194(1):79-82. PubMed ID: 8392846
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.
de Medeiros AS; Wyman AR; Alaamery MA; Allain C; Ivey FD; Wang L; Le H; Morken JP; Habara A; Le C; Cui S; Lerner A; Hoffman CS
Cell Signal; 2017 Dec; 40():73-80. PubMed ID: 28867658
[TBL] [Abstract][Full Text] [Related]
16. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.
Erdogan S; Houslay MD
Biochem J; 1997 Jan; 321 ( Pt 1)(Pt 1):165-75. PubMed ID: 9003416
[TBL] [Abstract][Full Text] [Related]
17. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
18. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
Suvarna NU; O'Donnell JM
J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
[TBL] [Abstract][Full Text] [Related]
19. Characterization of CHO-K1 cells stably expressing PDE-IV enzymes. Whole-cell cAMP determinations vs broken-cell enzymatic assays.
Pon DJ; Plant M; Tkach J; Boulet L; Muise E; Allen RA; Rodger IW
Cell Biochem Biophys; 1998; 29(1-2):159-78. PubMed ID: 9631244
[TBL] [Abstract][Full Text] [Related]
20. Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors.
Allen RA; Merriman MW; Perry MJ; Owens RJ
Biochem Pharmacol; 1999 Jun; 57(12):1375-82. PubMed ID: 10353258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
